NCT06174571

Brief Summary

This work aims to:

  1. 1.Evaluation of the role of pregnancy associated plasma protein A( PAPPA ) in diagnosis \& early detection of breast cancer.
  2. 2.Evaluation of the relationship between ( PAPPA ) levels and stages of breast cancer.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
90

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Feb 2024

Typical duration for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 2, 2023

Completed
16 days until next milestone

First Posted

Study publicly available on registry

December 18, 2023

Completed
2 months until next milestone

Study Start

First participant enrolled

February 1, 2024

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2026

Completed
28 days until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2026

Completed
Last Updated

December 18, 2023

Status Verified

December 1, 2023

Enrollment Period

2 years

First QC Date

December 2, 2023

Last Update Submit

December 8, 2023

Conditions

Breast Cancer

Outcome Measures

Primary Outcomes (1)

  • Quantitative measurement of pregnancy associated plasma protein A in female patients with breast cancer.

    Quantitative measurement of pregnancy associated plasma protein A in female patients with breast cancer.

    baseline

Study Arms (2)

1

patients diagnosed with breast cancer at different stages of the disease.

2

apparently healthy females as a control group.

Eligibility Criteria

Age18 Years - 70 Years
Sexfemale
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

female patients with breast cancer at different stages of the disease.

You may qualify if:

  • female patients with breast cancer who were diagnosed by histopathological studies and did not receive any treatment.

You may not qualify if:

  • Patients who received chemotherapy or radiotherapy.
  • Patients with known other organ malignancy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Central Study Contacts

Aya Hasan Abdulhady

CONTACT

01146471617ayahhasan99@gmail.com

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Lecturer

Study Record Dates

First Submitted

December 2, 2023

First Posted

December 18, 2023

Study Start

February 1, 2024

Primary Completion

February 1, 2026

Study Completion

March 1, 2026

Last Updated

December 18, 2023

Record last verified: 2023-12